Reverting immune suppressionto elicit brain metastasis control
About us*
The RISEbrain consortium brings together the highly complementary expertise of 6 teams with inter-sectorial (basic and clinical) and interdisciplinary focus (life sciences, computational sciences, engineering) to tackle the growing societal challenge posed by brain metastases.

Partners*
RISEbrain brings together 6 partners with diverse backgrounds and expertise. Learn more about our team on our website.
Positions available*
We currently have job openings available! If you are interested check out our website for more information on how to apply.
Consortium achievements*
At RISEBrain, each laboratory has achieved significant scientific achievements in their respective fields of study. Visit our website to learn more about our achievements and ongoing research.
- Marc Schmitz
Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma
Journal for Immunotherapy of Cancer
- Marc Schmitz
Tumor-infiltrating plasmacytoid dendritic cells are associated with survival in human colon cancer
J Immunother Cancer
- Manuel Valiente
TIMP1 mediates astrocyte-dependent local immunosuppression in brain metastasis acting on infiltrating CD8+ T cells
Cancer Discovery
- Farhan Ali et al
Tackling the focal shift effect for metalenses
- Manuel Valiente
Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism.
Monteiro, Miarka et al.
Nature Medicine
News & Outreach*
Our RISEbrain partners have been published and featured in top media outlets and conferences. Learn more on our website.
25/02/2025
- Manuel Valiente
News
The brain metastatic niche as a source of systemic vulnerabilities and opportunities
EACR Virtual Conference ‘The Systemic Consequences of Cancer’
21/02/2025
- Hind Medyouf